

## Research Article

# Spingosine-1-Phosphate/Spingosine-1-Phosphate Receptor 2 Axis Can Promote Mouse and Human Primary Mast Cell Angiogenic Potential through Upregulation of Vascular Endothelial Growth Factor-A and Matrix Metalloproteinase-2

Alena Chumanevich, Piper Wedman, and Carole A. Oskeritzian

Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Building 2, Room C10, 6439 Garners Ferry Road, Columbia, SC 29209, USA

Correspondence should be addressed to Carole A. Oskeritzian; [carole.oskeritzian@uscmcd.sc.edu](mailto:carole.oskeritzian@uscmcd.sc.edu)

Received 14 August 2015; Revised 30 November 2015; Accepted 21 December 2015

Academic Editor: Kazuyuki Kitatani

Copyright © 2016 Alena Chumanevich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mast cells (MC) are present in most vascularized tissues around the vasculature likely exerting immunomodulatory functions. Endowed with diverse mediators, resident MC represent first-line fine-tuners of local microenvironment. Spingosine-1-phosphate (SIP) functions as a pluripotent signaling sphingolipid metabolite in health and disease. SIP formation occurs at low levels in resting MC and is upregulated upon activation. Its export can result in type 2 SIP receptor- (SIPR2-) mediated stimulation of MC, further fueling inflammation. However, the role of SIPR2 ligation in proangiogenic vascular endothelial growth factor- (VEGF-) A and matrix metalloproteinase- (MMP-) 2 release from MC is unknown. Using a preclinical MC-dependent model of acute allergic responses and *in vitro* stimulated primary mouse bone marrow-derived MC (BMMC) or human primary skin MC, we report that SIP signaling resulted in substantial amount of VEGF-A release. Similar experiments using *Sipr2*-deficient mice or BMMC or selective SIP receptor agonists or antagonists demonstrated that SIP/SIPR2 ligation on MC is important for VEGF-A secretion. Further, we show that SIP stimulation triggered transcriptional upregulation of VEGF-A and MMP-2 mRNA in human but not in mouse MC. SIP exposure also triggered MMP-2 secretion from human MC. These studies identify a novel proangiogenic axis encompassing MC/SIP/SIPR2 likely relevant to inflammation.

## 1. Introduction

Mast cells (MC) convey immunomodulatory functions through their unique ability to release, after activation, many mediators including cytokines, chemokines, and enzymes, some of which are prestored in cytoplasmic granules at homeostasis [1]. MC are *bona fide* sentinels present in most vascularized tissues prior to trauma, equipped with a vast selection of surface receptors, therefore sensing and quickly responding to local alterations [2]. Notorious for their key contributions to allergic responses, MC influence the course and chronicity of many inflammatory disorders [3–5].

We discovered that immunoglobulin E- (IgE-) dependent MC activation releases spingosine-1-phosphate (SIP), a bioactive sphingolipid mediator produced by spingosine

kinases that serves to further propagate MC-mediated inflammatory response [3, 4, 6]. SIP exerts its pleiotropic actions imparted by ligation to five G-protein-coupled receptors (GPCRs), SIPR1–SIPR5, with subtype-specific distinct repertoire of heterotrimeric G protein coupling, in combination with tissue- and cell-type-specific receptor expression patterns [7]. Our recent studies established MC as critical to the onset of acute pulmonary allergic response [3] through autocrine/paracrine binding of SIP on MC surface SIP receptor type 2 (SIPR2). This interaction led to MC-derived T-cell-attracting chemokine release partly through signal transducer and activator of transcription 3 (Stat3) signaling [4]. Suppression of MC SIPR2 signaling by SIPR2 genetic ablation or pharmacological antagonism significantly impaired T-cell recruitment through decreased release

of T-cell chemoattractants in activated MC supernatants. Moreover, eliminating extracellular SIP with a monoclonal antibody (mAb) that binds and neutralizes SIP mitigated *ex vivo* and *in vivo* allergic MC activation, yielding significant inhibition of inflammatory infiltration and chemokine detection [4]. Of note, this mAb was shown to be effectively antiangiogenic in mouse xenograft and allograft tumor models [8, 9] as well as in a mouse model of wet age-related macular degeneration, that is, choroidal neovascularization [10].

Angiogenesis, or the formation and maintenance of blood vessel structures, is essential for the physiological functions of tissues and for the progression of diseases such as cancer and inflammation [11, 12]. SIP stimulates endothelial cell proliferation and survival, migration, and capillary-like tube formation via SIPR1 and SIPR3 *in vitro*, which is indicative of its angiogenic activity [13, 14]. SIP also maintains endothelial barrier function via SIPR1 [15, 16].

In addition to histamine, a potent vasoactive amine triggering vascular leakage and edema, and SIP, MC can generate an array of angiogenic factors, including vascular endothelial growth factor-A (VEGF-A), upon cross-linking of surface bound IgE on their high-affinity receptors (FcεRI) with allergen (Ag) and other stimuli [17–20]. VEGF-A regulates angiogenesis and vascular permeability by activating 2 receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk1 in mice) [21]. Interestingly, SIP can activate VEGFR-2 in the absence of its conventional ligand VEGF by receptor cross talk [22]. Ligation of SIPR2 on the cell membrane can induce ERK1/2 activation through activation of Gi protein. Activation of Gi can lead to Src activation that results in the phosphorylation of VEGFR-2. This transactivation of VEGFR-2 also contributes to vascular remodeling [23].

In the present study, we further investigated the role of SIP signaling through SIPR2 on MC and show for the first time that SIP stimulation of primary mouse and human MC results in the release of substantial amounts of VEGF-A. The relevance of these findings was substantiated using genetically SIPR2-deficient and congenic wild-type mouse model of acute allergic response [3, 4], as well as selective pharmacological receptor agonist and antagonist [3, 4, 24]. Moreover, our results provide new molecular insights pertaining to SIP-regulated VEGF-A release from primary human MC. Finally we report that SIP-dependent MC activation induces the release of matrix metalloproteinase- (MMP-) 2, endowed with extracellular and connective tissue matrix degrading properties [25], therefore potentially also contributing to neovascularization in inflammatory and cancer settings.

## 2. Materials and Methods

**2.1. Mice.** Age- and gender-matched C57BL/6J mice were obtained from the National Institutes of Health (NIH) National Cancer Institute (Frederick, MD, USA). SIPR2 knockout mice (Taconic Biosciences, Inc., Hudson, NY) and corresponding wild-type (WT) mice were on a mixed 129/SvEv-C57BL/6 background. All mice were maintained in a pathogen-free facility. Studies were performed in accordance with institutional animal care and use committee guidelines.

**2.2. Reagents.** Dinitrophenyl- (DNP-) specific mouse IgE was a generous gift from Dr. Daniel Conrad (VCU, Richmond, VA). DNP-human serum albumin (HSA) and ionomycin were obtained from Sigma-Aldrich (St Louis, MO). SIP was purchased from Enzo Life Sciences (Farmingdale, NY). JTE-013 and CYM-5442 were purchased from Tocris/Bio-Techne (Minneapolis, MN).

**2.3. Human Skin and Mouse Bone Marrow-Derived Mast Cells.** Human skin MC and mouse bone marrow-derived mast cells (BMMC) were isolated and cultured essentially as previously described [26, 27] and were more than 98% pure. Human MC and mouse BMMC were sensitized overnight with 1 μg/mL DNP-specific mouse IgE, washed to remove excess unbound IgE, and stimulated with 30 or 20 ng/mL DNP-HSA (Ag), respectively, for 24 hours. Ionomycin (1 μM), a receptor-independent stimulus, and SIP (100 nM) were also applied for 24 hours. Of note, vehicle consisted of DMSO/PBS-4 mg/mL fatty acid-free bovine serum albumin. All supernatants were collected after 24 hours of stimulation. Each experiment was performed at least three times, with triplicate determinations. For mRNA analysis, 3–5 × 10<sup>6</sup> human skin MC from 5 different donors were incubated for the indicated times in the presence or absence (vehicle, or culture medium alone) of SIP (100 nM).

**2.4. Acute Mast Cell-Dependent Allergic Response.** All injections were performed intraperitoneally in a final volume of 100 μL, as previously described [3, 4]. Briefly, mice were injected with DNP-specific IgE and 12 hours later with Ag in PBS. Mice were euthanized 2 hours later and blood was immediately collected by cardiac puncture for serum analysis.

**2.5. VEGF-A and MMP-2 Measurements.** Human and mouse angiogenic factors were measured by ELISA, according to manufacturer's instructions (Bio-Techne, Minneapolis, MN).

**2.6. Quantitative PCR Analysis.** Total RNA was isolated and purified with the miRNeasy Kit (Qiagen, Valencia, CA), following the manufacturer's procedure. The iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) was used according to the manufacturer's specifications to reverse-transcribe cDNA. QPCR was performed on a CFX Connect (Bio-Rad) with SensiFAST SYBR No-ROX Kit (Bioline). The following primers were used for real-time PCR amplification: human VEGF-A, forward primer 5'-AGGCCAGCACATAGGAGA-3' and reverse primer 5'-ACCGCCTCGGCTTGTCACAT-3'; human MMP-2, forward primer 5'-TACAGGATCATTGGCTACACACC-3' and reverse primer 5'-GGTCACATCGCTCCAGACT-3'; human GAPDH, forward primer 5'-TTGAGG-TCAATGAAGGGGTC-3' and reverse primer 5'-GAAGGT-GAAGGTCGGAGTCA-3'; mouse VEGF-A, forward primer 5'-GGCCTCCGAAACCATGAACT-3' and reverse primer 5'-CTGGGACCACTTGGCATGG-3'; mouse MMP-2, forward primer 5'-ACCTGAACACTTTCTATGGCTG-3' and reverse primer 5'-CTTCCGCATGGTCTCGATG-3'; and mouse GAPDH, forward primer 5'-CAGAAGGGGGCGGAGATGA-3' and reverse primer 5'-AGGCCGGTGCTGCTGAGTATGTC-3'. The real-time PCR conditions were as follows: initial step at 95°C for 10 min and cycles (*n* = 40)




FIGURE 1: Role of S1P/S1PR2 signaling in VEGF-A secretion. (a) Blood was collected from allergenically challenged WT (open bar,  $n = 5-6$  mice) and S1PR2-null (black bar,  $n = 5-6$  mice) mice, euthanized 2 hours after Ag challenge, and serum VEGF-A levels were measured in duplicate determination for each animal. (b) Bone marrow-derived mast cells (BMMC, three independent populations) from both genotypes were stimulated for 24 hours with vehicle (DMSO/PBS/4 mg/mL fatty acid-free BSA), S1P (100 nM), IgE/Ag, or ionomycin (Iono) and VEGF-A was measured in MC supernatants, in duplicate determinations. Error bars show standard error of means. \* $p < 0.05$ , \*\* $p < 0.005$ .

consisted of 10 s at 95°C, followed by 20 s annealing/extension at 59°C and extension at 72°C. All reactions were performed in duplicate. Data were analyzed with CFX Manager software (Bio-Rad) and are normalized expression directly proportional to the amount of mRNA of the target genes VEGF-A and MMP-2 relative to the amount of mRNA of the reference gene, GAPDH. Primers were synthesized and purchased from Thermo Fisher Scientific, Inc. (Waltham, MA), with melting temperatures ranging from 59.9 to 64.5°C.

**2.7. Statistical Analysis.** Data are expressed as means  $\pm$  SEM and were analyzed by using unpaired two-tailed Student's *t*-test for comparison of two groups (Prism 6; GraphPad Software, La Jolla, CA). Significance for statistical tests is shown in figures. Experiments were repeated at least three times in duplicate or triplicate with consistent results. *In vivo* experiments were repeated twice ( $n = 5-6$  mice per experimental group).

### 3. Results

**3.1. MC- and IgE-Dependent Acute Allergic Reactions Trigger Systemic VEGF-A Detection in WT Mice That Is Significantly Mitigated in S1pr2-Null Mice.** We previously reported that substantial levels of circulating chemokines were detected in the serum of WT mice 2 hours after eliciting a MC-dependent allergenic challenge [4]. We also showed that chemokine production was significantly decreased in the

absence of extracellular S1P [4] or in mice genetically ablated for *S1pr2* or pretreated with a selective S1PR2 antagonist [3]. Similarly, circulating levels of VEGF-A were measured in the serum of WT and *S1pr2*-null mice in the same preclinical model. Figure 1(a) shows that as early as 2 hours after Ag administration significant levels of VEGF-A were detected in the serum of sensitized WT while the absence of *S1pr2* severely mitigated serum VEGF-A levels in sensitized *S1pr2*-deficient mice. Of note, VEGF-A was undetectable in the serum of either genotype prior to allergenic challenge (data not shown). We further substantiated the relevance of *S1pr2* in VEGF-A secretion by stimulating *in vitro* mouse BMMC from both genotypes and measuring VEGF-A in activated BMMC supernatants. Figure 1(b) shows that S1P (100 nM) and IgE/Ag stimulation trigger significant release of VEGF-A in the supernatants of activated WT BMMC collected after 24 hours that was significantly decreased in *S1pr2*-deficient BMMC, further emphasizing the importance of S1PR2 signaling on MC for VEGF-A secretion. Of note, ionomycin, a calcium ionophore and receptor-independent MC stimulus, also triggered significant VEGF-A release from BMMC that was unaffected by the absence of S1PR2.

**3.2. In Vitro S1P- or IgE/Ag-Mediated Stimulation of Human Primary Mast Cells Results in the Release of Angiogenic Factors VEGF-A and MMP-2.** Next, to validate the physiological relevance of these findings, primary human mast cells were assessed for their ability to release angiogenic factors. As




FIGURE 2: Human MC secrete proangiogenic factors upon exposure to SIP in a S1PR2-dependent manner. (a) VEGF-A levels were measured in the supernatants of activated human MC in the absence (open bars, vehicle (DMSO/PBS/4 mg/mL fatty acid-free BSA)) or presence of a 30-minute pretreatment with CYM-5442 (filled bars, S1PR1 agonist, 1  $\mu$ M) or with JTE-013 (gray bars, S1PR2 antagonist, 1  $\mu$ M), followed by the indicated stimuli similar to Figure 1(b). (b) Matrix metalloproteinase- (MMP-) 2 levels were measured in supernatants of MC activated exactly as described in Figure 1(b). All supernatants were collected 24 hours after stimulation. Activation experiments were conducted using five independent human skin MC populations generated from five donors. Activation was conducted in triplicate determinations and measurements were conducted in duplicate determinations for each individual determination. When reaching significance, statistics are indicated in each figure. Error bars show standard error of means.  $***p < 0.0001$ .

shown in Figure 2(a), addition of exogenous SIP or Ag to sensitized human skin MC stimulates VEGF-A secretion that occurs at very low levels spontaneously. Ionomycin, a calcium ionophore and receptor-independent MC stimulus, also triggers VEGF-A release from human primary skin MC. The pretreatment of cells for 30 minutes in the presence of CYM-5442, a selective S1PR1 agonist, did not induce any VEGF-A secretion from MC on its own. Furthermore, exposure to CYM-5442 (1  $\mu$ M) prior to SIP or IgE/Ag did not alter the levels of VEGF-A released by either of these two stimuli. However, pretreating MC with JTE-013, a potent and selective antagonist for S1PR2, significantly inhibited both SIP- and IgE/Ag-mediated VEGF-A release from MC. Figure 2(b) demonstrates that SIP, IgE/Ag, and ionomycin stimuli also induce the secretion of large amounts of MMP-2 from human skin MC. Similar to Figure 2(a), pretreatment with CYM-5442 prior to stimulant exposure did not prevent MMP-2 secretion from human MC (Figure 2(b)). By contrast, preexposure to JTE-013, a pharmacological antagonist for S1PR2, significantly mitigated SIP- and IgE/Ag-dependent release of MMP-2 from human MC (Figure 2(b)), establishing that MC-derived VEGF-A and MMP-2 secretion requires functional MC-expressed S1PR2. It is noteworthy that SIP, itself potentially proangiogenic, promoted the release of VEGF-A and MMP-2 from human skin MC.

**3.3. SIP Stimulation Transcriptionally Upregulates VEGF-A and MMP-2 mRNA Expression in Human but Not in Mouse Primary Mast Cells.** Since *in vitro* stimulation of primary MC is conducted for 24 hours, we next sought to determine whether SIP could also activate VEGF-A and MMP-2 mRNA production during this time. To this end, primary human skin MC were stimulated for different periods of time in the presence of SIP (100 nM) and kinetics of VEGF-A (Figure 3(a)) and MMP-2 (Figure 3(b)) mRNA expression was investigated. Figures 3(a) and 3(b) show that stimulation of human skin MC for 3 hours triggered a significant increase in both VEGF-A and MMP-2 mRNA expression that decreased with increased incubation time but remained higher than in the absence of stimulation. Results were consistent for human skin MC derived from 5 different donors. In contrast, similar stimulation of BMDC did not result in upregulation of transcription for either of these two genes (Figures 3(c) and 3(d)). These results were replicated using three different BMDC populations.

## 4. Discussion

Inflammation first manifests itself with vascular alterations, including increased vascular permeability and edema [28]. MC are tissue-dwelling cells located around blood vessels and




FIGURE 3: Effect of S1P on VEGF-A and MMP-2 mRNA expression. Human (a, b) and mouse (c, d, BMMC) MC were stimulated in the presence of S1P (100 nM) for different periods of time at which VEGF-A (a, c) and MMP-2 (b, d) mRNA levels were measured by QPCR. mRNA was prepared from 3 independent BMMC and 5 independent human MC populations, in duplicate. Kinetics of S1P stimulation was repeated 3 to 4 times; each QPCR experiment was performed in duplicate determination for each individual sample. When reaching significance, statistics are indicated in each figure. Error bars show standard error of means. \*\*\* $p < 0.0001$ .

can release a number of vasoactive mediators that act directly on the vasculature, promoting vasodilation, increased endothelial permeability, and subsequent extravascular leakage of proteins and fluid [5]. Among the panoply of MC-derived bioactive mediators affecting the endothelium, histamine is released within minutes after activation [28]. We and others have shown that, upon allergenic activation of MC, concomitant sphingosine kinase activation occurs, leading to phosphorylation of sphingosine to rapidly produce S1P [6, 29–31]. We have also reported that S1P could be exported out of and act on the MC that produced it in an autocrine/paracrine manner [32] by ligation to S1PR1 or S1PR2, the two S1PR subtypes expressed on the MC surface [31]. This creates an inflammatory amplification loop that we have shown is essential to the onset of acute

allergic inflammation [3, 4, 31, 33]. Importantly, S1P is also constitutively released from human MC in the absence of stimulus [32]. This is an important point, as MC could be a source of local S1P at homeostasis in tissues, further prominent in inflamed sites [33].

Angiogenesis is an important feature of development and perpetuation of allergic inflammation [34]. The levels of VEGF-A are increased in the airways of asthmatic patients and MC constitute the majority of VEGF-A positive cells in bronchial biopsies from asthmatics [35]. We report for the first time that S1P stimulation of mouse and human primary MC is a potent inducer of VEGF-A release. Many studies have reported MC as a major source of VEGF [35–39]. We had previously shown that *S1pr2* deficiency in mice or in MC drastically reduced acute allergic responses and



early T-cell recruitment [3, 4]. Remarkably, our data indicate that acute allergen challenge of sensitized mice triggered immunodetectable levels of circulating VEGF-A as early as two hours after Ag challenge. In comparison, sensitized *Sipr2*-null mice display impaired systemic VEGF-A at the same time point after Ag challenge, suggesting an important function of S1PR2 signaling in VEGF-A secretion. Interestingly, similar findings have been reported in neuroblastoma cells, which also exhibited enhanced formation of SIP that ligated S1PR2 to induce VEGF expression [40]. In agreement with our study, the effect of SIP on VEGF mRNA expression also occurred at the transcriptional level [40] in human but not in mouse MC, suggesting contrasted and species-specific mechanisms regulating transcription. Supporting our findings, S1PR2 has been shown to be essential for normal and pathological angiogenesis [41, 42]. Our results are important because they show for the first time that MC/SIP/S1PR2 axis could promote proangiogenic VEGF-A secretion from MC.

The cross talk between SIP and VEGF signaling has been identified more than a decade ago but was typically assigned to S1PR1 [22, 43]. Whether they directly affected each other remained elusive. Our current study establishes that SIP can indeed stimulate VEGF-A secretion from primary MC through ligation to S1PR2, as CYM-5442, a selective pharmacological agonist of S1PR1 [24], did not induce VEGF-A secretion nor did it alter SIP- or IgE-Ag-mediated VEGF-A release. By contrast, JTE-013, a potent and selective antagonist for S1PR2, significantly impaired SIP and IgE/Ag-mediated VEGF-A secretion from primary MC. Of note and although S1PR2 functions in cancer are still obscure [40, 44, 45], our data suggest that SIP/S1PR2 signaling in MC may promote local VEGF production and therefore angiogenesis, potentially linking inflammation to cancer.

Moreover, SIP and IgE/Ag we show can stimulate the secretion of MMP-2 from human primary MC possibly extending their contribution as connectors of inflammation to metastatic cancer [46, 47]. Interestingly, active forms of MMP have been associated with the development of vasogenic edema and disruption of blood vessel integrity in stroke reperfusion therapy and S1PR2 has recently been shown to be critical in MMP-9 activation [48]. MC have long been known to produce MMP-9 [33, 49, 50] and MMP-2 [33, 51]. In agreement, we found that S1PR2 ligation by SIP resulted in MMP activation in primary MC.

It is important to mention that MC harbor nonconventional yet proangiogenic granule-associated mediators, including tryptase and chymase [46], particularly because they can activate latent forms of MMP [52]. It is tempting to speculate that SIP can directly activate MC to release MMP-2. Alternatively, because (1) we and others have previously reported that SIP contributes to MC activation and degranulation and (2) tryptase and chymase are granule-associated and as such released from MC upon activation, we can hypothesize an indirect influence of SIP on active MMP-2 release from MC through tryptase and/or chymase exocytosis, which, in turn, could activate MMP-2. These equally intriguing hypotheses are not mutually exclusive and highlight potentially new mechanistic insights warranting further investigations relevant to inflammation and cancer.

In sum, our findings demonstrate that SIP produced by MC in inflammatory settings can induce VEGF-A release from MC by ligation to S1PR2, further emphasizing a critical role of MC as pivotal cells influencing the conversion of acute inflammation to chronicity and perhaps carcinogenesis. Moreover, based on our previous reports demonstrating a downregulatory effect of *Sipr2* deficiency or functional antagonism on MC responsiveness, this report further suggests the importance of fine-tuning SIP signaling through MC S1PR2 as a relevant anti-inflammatory strategy and, potentially, a novel approach to chemoprevention of inflammation.

## Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

## Acknowledgments

The authors thank Dr. Daniel Conrad for kindly providing IgE. This work was supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases Grant R01 AI095494 to Carole A. Oskeritzian.

## References

- [1] S. J. Galli and M. Tsai, "IgE and mast cells in allergic disease," *Nature Medicine*, vol. 18, no. 5, pp. 693–704, 2012.
- [2] T. Marichal, M. Tsai, and S. J. Galli, "Mast cells: potential positive and negative roles in tumor biology," *Cancer Immunology Research*, vol. 1, no. 5, pp. 269–279, 2013.
- [3] C. A. Oskeritzian, M. M. Price, N. C. Hait et al., "Essential roles of sphingosine-1-phosphate receptor 2 in human mast cell activation, anaphylaxis, and pulmonary edema," *The Journal of Experimental Medicine*, vol. 207, no. 3, pp. 465–474, 2010.
- [4] C. A. Oskeritzian, N. C. Hait, P. Wedman et al., "The sphingosine-1-phosphate/sphingosine-1-phosphate receptor 2 axis regulates early airway T-cell infiltration in murine mast cell-dependent acute allergic responses," *The Journal of Allergy and Clinical Immunology*, vol. 135, no. 4, pp. 1008–1018.e1, 2015.
- [5] S. J. Galli, M. Grimbaldston, and M. Tsai, "Immunomodulatory mast cells: negative, as well as positive, regulators of immunity," *Nature Reviews Immunology*, vol. 8, no. 6, pp. 478–486, 2008.
- [6] C. A. Oskeritzian, S. E. Alvarez, N. C. Hait, M. M. Price, S. Milstien, and S. Spiegel, "Distinct roles of sphingosine kinases 1 and 2 in human mast-cell functions," *Blood*, vol. 111, no. 8, pp. 4193–4200, 2008.
- [7] V. A. Blaho and T. Hla, "An update on the biology of sphingosine 1-phosphate receptors," *Journal of Lipid Research*, vol. 55, no. 8, pp. 1596–1608, 2014.
- [8] S. Ponnusamy, S. P. Selvam, S. Mehrotra et al., "Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis," *EMBO Molecular Medicine*, vol. 4, no. 8, pp. 761–775, 2012.
- [9] B. Visentin, J. A. Vekich, B. J. Sibbald et al., "Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in

- multiple tumor lineages," *Cancer Cell*, vol. 9, no. 3, pp. 225–238, 2006.
- [10] N. O'Brien, S. T. Jones, D. G. Williams et al., "Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies," *The Journal of Lipid Research*, vol. 50, no. 11, pp. 2245–2257, 2009.
- [11] W. Risau, "Mechanisms of angiogenesis," *Nature*, vol. 386, no. 6626, pp. 671–674, 1997.
- [12] D. Hanahan and J. Folkman, "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis," *Cell*, vol. 86, no. 3, pp. 353–364, 1996.
- [13] M.-J. Lee, J. R. Van Brocklyn, S. Thangada et al., "Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1," *Science*, vol. 279, no. 5356, pp. 1552–1555, 1998.
- [14] T. Kimura, T. Watanabe, K. Sato et al., "Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3," *Biochemical Journal*, vol. 348, no. 1, pp. 71–76, 2000.
- [15] X. Peng, P. M. Hassoun, S. Sammani et al., "Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury," *American Journal of Respiratory and Critical Care Medicine*, vol. 169, no. 11, pp. 1245–1251, 2004.
- [16] J.-F. Lee, Q. Zeng, H. Ozaki et al., "Dual roles of tight junction-associated protein, Zonula Occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity," *The Journal of Biological Chemistry*, vol. 281, no. 39, pp. 29190–29200, 2006.
- [17] J. Boesiger, M. Tsai, M. Maurer et al., "Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fcε receptor I expression," *The Journal of Experimental Medicine*, vol. 188, no. 6, pp. 1135–1145, 1998.
- [18] A. Grützkau, S. Krüger-Krasagakes, H. Baumeister et al., "Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206," *Molecular Biology of the Cell*, vol. 9, no. 4, pp. 875–884, 1998.
- [19] J. Cao, N. Papadopoulou, D. Kempuraj et al., "Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor," *The Journal of Immunology*, vol. 174, no. 12, pp. 7665–7675, 2005.
- [20] T. C. Theoharides, B. Zhang, D. Kempuraj et al., "IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 9, pp. 4448–4453, 2010.
- [21] Y. B. Shaik-Dasthagirisaheb, G. Varvara, G. Murmura et al., "Vascular endothelial growth factor (VEGF), mast cells and inflammation," *International Journal of Immunopathology and Pharmacology*, vol. 26, no. 2, pp. 327–335, 2013.
- [22] T. Tanimoto, Z.-G. Jin, and B. C. Berk, "Transactivation of Vascular Endothelial Growth Factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS)," *The Journal of Biological Chemistry*, vol. 277, no. 45, pp. 42997–43001, 2002.
- [23] S. Spiegel and S. Milstien, "Sphingosine-1-phosphate: an enigmatic signalling lipid," *Nature Reviews Molecular Cell Biology*, vol. 4, no. 5, pp. 397–407, 2003.
- [24] P. J. Gonzalez-Cabrera, S. M. Cahalan, N. Nguyen et al., "SIP<sub>1</sub> receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis," *Molecular Pharmacology*, vol. 81, no. 2, pp. 166–174, 2012.
- [25] R. Visse and H. Nagase, "Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry," *Circulation Research*, vol. 92, no. 8, pp. 827–839, 2003.
- [26] W. Zhao, C. A. Oskeritzian, A. L. Pozez, and L. B. Schwartz, "Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines," *The Journal of Immunology*, vol. 175, no. 4, pp. 2635–2642, 2005.
- [27] Y. T. Falanga, N. S. Chaimowitz, N. Charles et al., "Lyn but not Fyn kinase controls IgG-mediated systemic anaphylaxis," *The Journal of Immunology*, vol. 188, no. 9, pp. 4360–4368, 2012.
- [28] S. J. Galli, M. Tsai, and A. M. Piliponsky, "The development of allergic inflammation," *Nature*, vol. 454, no. 7203, pp. 445–454, 2008.
- [29] C. A. Oskeritzian, S. Milstien, and S. Spiegel, "Sphingosine-1-phosphate in allergic responses, asthma and anaphylaxis," *Pharmacology & Therapeutics*, vol. 115, no. 3, pp. 390–399, 2007.
- [30] M. M. Price, C. A. Oskeritzian, S. Milstien, S. Spiegel, and M. M. Price, "Sphingosine-1-phosphate synthesis and functions in mast cells," *Future Lipidology*, vol. 3, no. 6, pp. 665–674, 2008.
- [31] P. S. Jolly, M. Bektas, A. Olivera et al., "Transactivation of sphingosine-1-phosphate receptors by FcεRI triggering is required for normal mast cell degranulation and chemotaxis," *The Journal of Experimental Medicine*, vol. 199, no. 7, pp. 959–970, 2004.
- [32] P. Mitra, C. A. Oskeritzian, S. G. Payne, M. A. Beaven, S. Milstien, and S. Spiegel, "Role of ABCC1 in export of sphingosine-1-phosphate from mast cells," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 44, pp. 16394–16399, 2006.
- [33] C. A. Oskeritzian, "Mast cell plasticity and sphingosine-1-phosphate in immunity, inflammation and cancer," *Molecular Immunology*, vol. 63, no. 1, pp. 104–112, 2015.
- [34] D. Ribatti, I. Puxeddu, E. Crivellato, B. Nico, A. Vacca, and F. Levi-Schaffer, "Angiogenesis in asthma," *Clinical & Experimental Allergy*, vol. 39, no. 12, pp. 1815–1821, 2009.
- [35] A. Zanini, A. Chetta, M. Saetta et al., "Chymase-positive mast cells play a role in the vascular component of airway remodeling in asthma," *The Journal of Allergy and Clinical Immunology*, vol. 120, no. 2, pp. 329–333, 2007.
- [36] B. N. Feltis, D. Wignarajah, L. Zheng et al., "Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma," *American Journal of Respiratory and Critical Care Medicine*, vol. 173, no. 11, pp. 1201–1207, 2006.
- [37] A. Detoraki, R. I. Staiano, F. Granata et al., "Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects," *Journal of Allergy and Clinical Immunology*, vol. 123, no. 5, pp. 1142–1149.e5, 2009.
- [38] K. S. Lee, S. R. Kim, S. J. Park et al., "Mast cells can mediate vascular permeability through regulation of the PI3K-HIF-1α-VEGF axis," *American Journal of Respiratory and Critical Care Medicine*, vol. 178, no. 8, pp. 787–797, 2008.
- [39] F. Wimazal, J.-H. Jordan, W. R. Sperr et al., "Increased angiogenesis in the bone marrow of patients with systemic mastocytosis," *The American Journal of Pathology*, vol. 160, no. 5, pp. 1639–1645, 2002.

- [40] M.-H. Li, T. Hla, and F. Ferrer, "Sphingolipid modulation of angiogenic factor expression in neuroblastoma," *Cancer Prevention Research*, vol. 4, no. 8, pp. 1325–1332, 2011.
- [41] A. Skoura, T. Sanchez, K. Claffey, S. M. Mandala, R. L. Proia, and T. Hla, "Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina," *The Journal of Clinical Investigation*, vol. 117, no. 9, pp. 2506–2516, 2007.
- [42] G. Zhang, L. Yang, G. S. Kim et al., "Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation," *Blood*, vol. 122, no. 3, pp. 443–455, 2013.
- [43] J. Igarashi, P. A. Erwin, A. P. V. Dantas, H. Chen, and T. Michel, "VEGF induces S1P<sub>1</sub> receptors in endothelial cells: implications for cross-talk between sphingolipid and growth factor receptors," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 19, pp. 10664–10669, 2003.
- [44] W. Du, N. Takuwa, K. Yoshioka et al., "S1P<sub>2</sub>, the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice," *Cancer Research*, vol. 70, no. 2, pp. 772–781, 2010.
- [45] G. Cattoretti, J. Mandelbaum, N. Lee et al., "Targeted disruption of the S1P<sub>2</sub> sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation," *Cancer Research*, vol. 69, no. 22, pp. 8686–8692, 2009.
- [46] M. Ammendola, C. Leporini, I. Marech et al., "Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenic strategy," *BioMed Research International*, vol. 2014, Article ID 154702, 16 pages, 2014.
- [47] C. A. Oskeritzian, "Mast cells and wound healing," *Advances in Wound Care*, vol. 1, no. 1, pp. 23–28, 2012.
- [48] G. S. Kim, L. Yang, G. Zhang et al., "Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke," *Nature Communications*, vol. 6, article 7893, 2015.
- [49] D. Baram, G. G. Vaday, P. Salamon, I. Drucker, R. Hershkovich, and Y. A. Mekori, "Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF- $\alpha$ ," *The Journal of Immunology*, vol. 167, no. 7, pp. 4008–4016, 2001.
- [50] N. Di Girolamo, I. Indoh, N. Jackson et al., "Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration," *The Journal of Immunology*, vol. 177, no. 4, pp. 2638–2650, 2006.
- [51] E. Tchougounova, A. Lundquist, I. Fajardo, J.-O. Winberg, M. Åbrink, and G. Pejler, "A key role for mast cell chymase in the activation of pro-matrix metalloproteinase-9 and pro-matrix metalloproteinase-2," *The Journal of Biological Chemistry*, vol. 280, no. 10, pp. 9291–9296, 2005.
- [52] D. Ribatti and G. Ranieri, "Tryptase, a novel angiogenic factor stored in mast cell granules," *Experimental Cell Research*, vol. 332, no. 2, pp. 157–162, 2015.





**Hindawi**  
Submit your manuscripts at  
<http://www.hindawi.com>

